A new international trial is recruiting healthy adults aged 55 to 80 to test if the drug Trontinemab can prevent the onset of Alzheimer’s before memory loss occurs. By identifying participants with specific biomarkers, researchers hope to stop the development of toxic brain plaques, potentially shifting the focus of dementia care from treatment to prevention.